

J u n e 2 6 , 2 0 0 8

**Application filed for a transdermal absorption-type continuous-action drug
to treat cancer pain
(Development code: HFT-290)**

Hisamitsu Pharmaceutical Co., Inc. (Hisamitsu; TSE:4530) announced that as of today Hisamitsu has filed an application for new drug approval with Ministry of Health, Labour and Welfare for use of a transdermal absorption-type continuous-action drug for the treatment of cancer pain (development code: HFT-290).

HFT-290 is a medicinal narcotic drug preparation that uses fentanyl citrate, a synthetic narcotic, having potent analgesic effects. It was developed as a tape product, using Hisamitsu's Transdermal Drug Delivery System (TDDS) technology.

After the product will be launched on the market, Hisamitsu and Kyowa Hakko Kogyo Co., Ltd.(TSE:4151) are planning to carry out independent product distribution and information provision/gathering activities under a one-brand, two-channel setup.